Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 327

1.

Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.

Saif MW, Lansigan F, Ruta S, Lamb L, Mezes M, Elligers K, Grant N, Jiang ZL, Liu SH, Cheng YC.

Phytomedicine. 2010 Mar;17(3-4):161-9. doi: 10.1016/j.phymed.2009.12.016. Epub 2010 Jan 22.

PMID:
20092990
2.

A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.

Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA.

Cancer Chemother Pharmacol. 2012 Dec;70(6):875-81. doi: 10.1007/s00280-012-1979-7. Epub 2012 Sep 28.

PMID:
23053263
3.

Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.

Starling N, Watkins D, Cunningham D, Thomas J, Webb J, Brown G, Thomas K, Oates J, Chau I.

J Clin Oncol. 2009 Nov 20;27(33):5499-505. doi: 10.1200/JCO.2008.21.5384. Epub 2009 Oct 26.

PMID:
19858399
4.

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.

Saif MW, Li J, Lamb L, Kaley K, Elligers K, Jiang Z, Bussom S, Liu SH, Cheng YC.

Cancer Chemother Pharmacol. 2014 Feb;73(2):373-80. doi: 10.1007/s00280-013-2359-7. Epub 2013 Dec 3.

5.

A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.

O'connor T, Rustum Y, Levine E, Creaven P.

Cancer Chemother Pharmacol. 2008 Jan;61(1):125-31. Epub 2007 Apr 11.

PMID:
17426973
6.

A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.

Amarantidis K, Xenidis N, Chelis L, Chiotis A, Tentes A, Chatzaki E, Kortsaris A, Polychronidis A, Karakitsos P, Kakolyris S.

Acta Oncol. 2010;49(2):245-51. doi: 10.3109/02841860903253553.

PMID:
19839918
7.

Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.

Sym SJ, Ryu MH, Kang HJ, Lee SS, Chang HM, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK.

Cancer Chemother Pharmacol. 2010 Jul;66(2):373-80. doi: 10.1007/s00280-009-1171-x. Epub 2009 Nov 21.

PMID:
19936751
8.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Deenen MJ, Kl├╝mpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW.

Invest New Drugs. 2012 Aug;30(4):1557-65. doi: 10.1007/s10637-011-9723-4. Epub 2011 Aug 2.

9.

Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.

Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA.

Am J Clin Oncol. 2012 Oct;35(5):411-7.

PMID:
21552099
10.

Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.

Ernst T, Merx K, Gnad-Vogt U, Lukan N, Kripp M, Schultheis B, Hochhaus A, Hofheinz RD.

Br J Cancer. 2007 Dec 3;97(11):1475-9. Epub 2007 Nov 13.

11.

Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.

Kakolyris S, Souglakos J, Kouroussis C, Androulakis N, Samonis G, Vardakis N, Amarantidis K, Agelaki S, Mavroudis D, Xenidis N, Georgoulias V.

Oncology. 2004;66(4):253-9.

PMID:
15218291
12.

A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.

Amarantidis K, Houhouli K, Papatheodorou K, Miloussis A, Matthaios D, Chatzaki E, Lyrantzopoulos N, Tsaroucha A, Tentes A, Kakolyris S.

Oncol Res. 2006;16(6):281-7.

PMID:
17476973
13.

A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.

Michaelson MD, Ryan DP, Fuchs CS, Supko JG, Garcia-Carbonero R, Paul Eder J, Clark JW.

Cancer. 2003 Jan 1;97(1):148-54.

14.

A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.

Infante JR, Jones SF, Bendell JC, Greco FA, Yardley DA, Lane CM, Spigel DR, Hainsworth JD, Burris HA 3rd.

Cancer Chemother Pharmacol. 2012 Jan;69(1):137-44. doi: 10.1007/s00280-011-1674-0. Epub 2011 May 28.

PMID:
21626051
15.

Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.

Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ.

Am J Clin Oncol. 2008 Feb;31(1):1-5. doi: 10.1097/COC.0b013e31805c142f.

PMID:
18376220
16.

A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.

Saridaki Z, Malamos N, Kourakos P, Polyzos A, Ardavanis A, Androulakis N, Kalbakis K, Vamvakas L, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2012 Jan;69(1):35-42. doi: 10.1007/s00280-011-1663-3. Epub 2011 May 18.

PMID:
21590447
17.
18.

[Phase I study of postoperative concurrent chemoradiation with capecitabine as adjuvant treatment for stage II/III operable rectal cancer].

Jin J, Li YX, Liu YP, Wang WH, Li T, Li N, Song YW.

Zhonghua Zhong Liu Za Zhi. 2006 May;28(5):393-6. Chinese.

PMID:
17045010
19.

A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.

Maltezos E, Amarantidis K, Trichas M, Vasiliadis M, Toromanidou M, Chatzaki E, Karayiannakis A, Tsaroucha A, Romanidis K, Kakolyris S.

Oncology. 2005;69(6):463-9. Epub 2005 Dec 21.

PMID:
16374040
20.

Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.

Sayar H, Shen Z, Lee SJ, Royce M, Rabinowitz I, Lee F, Smith H, Eberhardt S, Maestas A, Lu H, Verschraegen C.

Invest New Drugs. 2009 Apr;27(2):153-8. doi: 10.1007/s10637-008-9172-x. Epub 2008 Sep 5.

PMID:
18773144

Supplemental Content

Support Center